Walmart’s stock slides as U.S. sales are hit by falling drug prices

Walmart’s latest quarterly report shows that even the largest retailers are not immune to pricing pressure in the pharmacy aisle. The company posted comparable U.S. sales growth of just 2.6% for its second quarter—its slowest pace in over six years. According to the report, the deceleration was tied to falling drug prices, which reduced the dollar value of pharmacy sales even if the number of prescriptions filled remained steady. For a grocery-and-general-merchandise giant, such a slowdown in a high-frequency category can weigh on overall same-store momentum.

From an educational standpoint, this illustrates how deflation in a single product category can ripple through a retailer's headline metric. For investors, the key question is whether this is a temporary effect from pricing changes or a sign of softer consumer spending. The market’s negative reaction suggests it is watching for confirmation that non-pharmacy categories, such as groceries and general merchandise, continue to hold up. Future earnings reports will show whether Walmart can offset the drag through volume growth and cost discipline.